Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7084956 | 1.00 | SLC6A3 (0.73) | SLC6A3 | |
| SCHEMBL7684279 | 0.86 | SLC6A3 (0.73) | SLC6A3 | |
| SCHEMBL3832402 | 0.85 | SLC6A3 (1.00) | SLC6A3 | |
| SCHEMBL3832400 | 0.85 | SLC6A3 (1.00) | SLC6A3 | |
| SCHEMBL3827721 | 0.85 | SLC6A3 (1.00) | SLC6A3 | |
| SCHEMBL13679363 | 0.85 | SLC6A3 (1.00) | SLC6A3 | |
| SCHEMBL3827724 | 0.85 | SLC6A3 (1.00) | SLC6A3 | |
| SCHEMBL3827726 | 0.85 | SLC6A3 (1.00) | SLC6A3 | |
| SCHEMBL3833873 | 0.80 | SLC6A3 (0.72) | SLC6A3 | |
| SCHEMBL3832793 | 0.80 | SLC6A3 (0.72) | SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605621-B1 | Safe and effective detoxification after treating drug addiction, or diseases wherein cocaine is administered | GEORGETOWN UNIVERSITY | 2003-08-12 | — | — | US | disclosed |
| US-20030144289-A1 | Monomeric and dimeric heterocycles, and therapeutic uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-31 | — | — | US | disclosed |
| US-6440996-B1 | Monomeric and dimeric heterocycles, and therapeutic uses thereof | GEORGETOWN UNIVERSITY | 2002-08-27 | — | — | US | disclosed |
| EP-1119553-A1 | MONOMERIC AND DIMERIC HETEROCYCLES, AND THERAPEUTIC USES THEREOF | GEORGETOWN UNIVERSITY (US) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000020390-A1 | MONOMERIC AND DIMERIC HETEROCYCLES, AND THERAPEUTIC USES THEREOF | GEORGETOWN UNIVERSITY (US) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144289-A1 | Monomeric and dimeric heterocycles, and therapeutic uses thereof | HAX1, MLX, XDH | SLC6A3 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.